Study | Number of patients | Mean follow-up [range] (months) | Patients improved >50% | Change attack frequency (%) | Change attack severity (%) | Preventative treatment reduction* |
---|---|---|---|---|---|---|
Magis et al35 36 | 14 | 36.62 [11–64] | 12/14 (86%) | −94.6 | +2.3 | 29% |
Burns et al37 38 | 14 | 17.5 [4–35] | 10/14 (71%) | −33 | +8 | 43% (triptans) |
de Quintana-Schmidt et al39 | 4 | 6+ | 4/4 (100%) | −56 | −48 | 21% |
Fontaine et al40 | 13 | 14.6 [3–34] | 10/13 (76%) | −68 | −49 | 62% |
Mueller 201356 | 24 | 21.5 [4–47] | 21/24 (88%) | −40 | −38 | 40% reduction daily triptan dose |
NHNN (authors) cohort (submitted for publication) | 63 | 46 [2–129] | 36/63 (57%) | −49 | −25 | 83% (41% triptans) |
*Figures show the percentage of patients on preventative drugs at baseline who have reduced or stopped medication at follow-up unless otherwise stated.
NHNN, National Hospital for Neurology and Neurosurgery.